Interestingly, when evaluating by size alone, we identified a greater number of patients with GSK-3β expression in T1/T2 tumors (95%CI 0.86–1.32, p = 0.523), compared to T3/T4 cancers, but without statistical significance. The gene discussed is GSK3B; the disease is cancer.